18-Mar-2025 7:15 AM CST - Business Wire Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Ph
25-Feb-2025 7:15 AM CST - Business Wire Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimers Disease Using GLP-1 Agonists and Combinations Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast Is Alzheimers next for GLP-1s and Combos? on February 27, 2025 to discuss the potential treatment of Al
4-Feb-2025 7:15 AM CST - Business Wire Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11-12, 2025 in a virtual format. Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference Presentation Date: Tuesda
25-Nov-2024 7:15 AM CST - Business Wire Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Conference being held on December 3 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL. On Tuesday, December 3 at 12:55
6-Nov-2024 7:00 AM CST - Business Wire Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024. Recent Corporate Highlights Announced positive results from an investigator initiated double-blind study of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimers
24-Sep-2024 7:15 AM CST - Business Wire Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will participate in a fireside chat at the Chardan 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:00pm ET. The fireside chat will be moder
18-Mar-2025 7:15 AM CST - Business Wire Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Ph
25-Feb-2025 7:15 AM CST - Business Wire Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimers Disease Using GLP-1 Agonists and Combinations Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast Is Alzheimers next for GLP-1s and Combos? on February 27, 2025 to discuss the potential treatment of Al
4-Feb-2025 7:15 AM CST - Business Wire Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11-12, 2025 in a virtual format. Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference Presentation Date: Tuesda
25-Nov-2024 7:15 AM CST - Business Wire Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Conference being held on December 3 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL. On Tuesday, December 3 at 12:55
6-Nov-2024 7:00 AM CST - Business Wire Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results Coya Therapeutics, Inc. (Nasdaq: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024. Recent Corporate Highlights Announced positive results from an investigator initiated double-blind study of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimers
24-Sep-2024 7:15 AM CST - Business Wire Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will participate in a fireside chat at the Chardan 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 2:00pm ET. The fireside chat will be moder
